【藥品性質提示】 ★LASA藥品：REL04 【184/22】Relvar Ellipta 紫 吸入劑 (形似) 點擊看LASA藥品外觀比較圖 【藥品訊息】 Relvar Ellipta 92/22 吸入劑 衛教單張

氣喘或慢性阻塞性肺病 Asthma, Chronic obstructive pulmonary disease

Fluticasone: A corticosteroid with anti-inflammatory activity, immunosuppressive properties, and antiproliferative actions.
Vilanterol: A long-acting beta2-agonist, relaxes bronchial smooth muscle by selective action on beta2-receptors with little effect on heart rate.

1. Hypersensitivity to fluticasone, vilanterol, or any component of the formulation
2. Severe hypersensitivity to milk proteins
3. Primary treatment of status asthmaticus or other acute episodes of COPD or asthma where intensive measures are required

Adverse events have not been observed in animal reproduction studies.

It is not known if sufficient quantities of fluticasone or vilanterol are absorbed following inhalation to produce detectable amounts in breast milk.

Cardiovascular: Hypertension, peripheral edema, extrasystoles, supraventricular extrasystole, ventricular premature contractions

Central nervous system: Headache

Gastrointestinal: Oropharyngeal candidiasis, diarrhea, upper abdominal pain

Infection: Influenza

Neuromuscular & skeletal: Arthralgia, back pain, bone fracture

Respiratory: Nasopharyngitis, upper respiratory tract infection, pneumonia, oropharyngeal pain, pharyngitis, chronic obstructive pulmonary disease, cough, sinusitis, bronchitis, acute sinusitis, allergic rhinitis, rhinitis, viral respiratory tract infection, voice disorder

Miscellaneous: Fever

One inhalation once daily; MAX 1 inhalation once daily
Asthma:
1. Recommended starting dose is determined according to asthma severity.
2. For patients not adequately controlled on the lower combination dose, consider the higher dose combination.
3. Reevaluate treatment regimen if previously effective dose does not provide adequate improvement in asthma control.
Chronic obstructive pulmonary disease:
1. Depend on symptoms and exacerbation risk, may use a single long-acting bronchodilator (LABA or LAMA) or dual-acting bronchodilator (LABA and LAMA), with or without an inhaled corticosteroid
2. In addition, a short-acting bronchodilator is used for symptom relief

1. Mild impairment: There are no dosage adjustments provided in the manufacturer's labeling.
2. Moderate to severe impairment: There are no dosage adjustments provided in the manufacturer's labeling; however, systemic fluticasone exposure may be increased up to threefold in patients with hepatic impairment; use with caution and monitor closely.